Medical technology company Proteomics International (ASX: PIQ) has teamed up with biotech stock Dimerix (ASX: DXB) to investigate the potential of their combined technology in treating kidney disease.
Dimerix has developed the DMX-200 drug for treating the disease while Proteomics has created a PromarkerD which is a predictive and diagnostic tool that measures a protein biomarker panel in the blood, which assists in early detection diabetic kidney disease.
In a recent Phase 2a clinical trial, the DMX-200 was shown as a safe with “promising efficacy signals” especially in diabetic kidney disease patients.
Meanwhile, the PromarkerD has predicted rapid kidney function decline in clinical studies – up to four years prior to onset.
When combined with the DMX-200, the companies anticipate they may be able to delay disease onset or prevent it entirely.